Manatt Health
35 States Sign On to CMS's Medicaid Gene Therapy Payment Model for Sickle Cell Disease
Manatt summarizes CMS's announcement that 35 states have joined its Cell and Gene Therapy Access Model, an 11-year initiative using value-based rebate contracts with bluebird bio and Vertex to offset the high cost of sickle cell gene therapies covered under Medicaid. The piece outlines the rollout timeline—State Agreements by June 1, funding awards by July 1, and staggered start dates through January 2026—and notes CMS is exploring expansion to additional gene therapy categories, which has direct implications for state Medicaid pharmacy budgets and rebate negotiations.
This is outside commentary from Manatt Health, not part of Medicaid Monitor's independently scored news coverage.